AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
AYTU BIOPHARMA, INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026
$1.96−0.08 (-3.92%)
Close on Oct 19, 2026
- Market cap
- $37.82M
- P/E (TTM)
- –
- Dividend yield
- –
Aytu Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Market Cap | $21.30M | $164.85M |
| Enterprise Value | $5.95M | $87.06M |
| PS Ratio | 0.37 | 3.60 |
| PB Ratio | 0.60 | 2.03 |
| P/FCF Ratio | 6.55 | 17.44 |
| P/OCF Ratio | 6.49 | 13.32 |
Enterprise value
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| EV / Sales | 0.10 | 2.43 |
| EV / FCF | 1.83 | 20.97 |
Income (trailing twelve months)
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Revenue | $57.57M | $57.94M |
| Gross Profit | $36.82M | $90.47M |
| Operating Income | -$8.32M | -$21.44M |
| Pretax Income | -$14.23M | -$14.45M |
| Net Income | -$14.25M | -$22.46M |
| EBITDA | -$4.39M | -$16.91M |
| EPS (Diluted) | -$1.66 | -$0.83 |
Margins
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Gross Margin | 64.0% | 52.3% |
| Operating Margin | -14.4% | -44.5% |
| Pretax Margin | -24.7% | -13.0% |
| Profit Margin | -24.8% | -39.2% |
| EBITDA Margin | -7.62% | -31.3% |
| FCF Margin | 5.65% | -8.85% |
Returns
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -52.6% | -53.1% |
| Return on Assets (ROA) | -12.4% | -41.0% |
| Return on Invested Capital (ROIC) | -63.5% | -32.0% |
| Return on Capital Employed (ROCE) | -16.5% | -37.8% |
Growth
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -13.3% | 6.01% |
| Revenue Growth (3Y CAGR) | -18.8% | 2.25% |
| Revenue Growth (5Y CAGR) | -2.59% | 6.42% |
Balance sheet
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $26.31M | $62.42M |
| Total Debt | $10.96M | $120.13M |
| Net Cash (Debt) | $15.35M | $15.68M |
| Net Cash Per Share | $1.41 | $0.66 |
| Equity (Book Value) | $35.27M | $48.79M |
| Book Value Per Share | $3.25 | $1.36 |
| Tangible Book Value | -$6.13M | $23.06M |
| Working Capital | $7.10M | $75.77M |
Financial position
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Current Ratio | 1.13 | 3.30 |
| Quick Ratio | 0.90 | 2.39 |
| Debt / Equity | 0.31 | 0.51 |
| Debt / FCF | 3.37 | 5.05 |
| Interest Coverage | -4.39 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | $3.28M | -$12.35M |
| Capital Expenditures | -$29.00K | -$1.06M |
| Free Cash Flow | $3.25M | -$20.28M |
| FCF Per Share | $0.30 | -$0.42 |
Efficiency
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Asset Turnover | 0.50 | 0.38 |
| Inventory Turnover | 2.27 | 2.67 |
| Revenue Per Employee | $757.50K | $398.96K |
| Profits Per Employee | -$187.53K | -$703.34K |
| Employee Count | 76 | 74 |
Dividends and yields
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Earnings Yield | -66.9% | -22.7% |
| FCF Yield | 15.3% | -9.07% |
Shares
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 10,866,700 | 58,179,650 |
| Shares Change (YoY) | 96.2% | 11.1% |
| Shares Change (QoQ) | -0.05% | 0.54% |
| Float | 9,220,990 | 49,173,100 |
| Shares Held by Insiders | 15.1% | 11.6% |
| Shares Held by Institutions | 45.3% | 59.4% |
Taxes
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Income Tax | $21.00K | $91.50K |
Scores
| Measure | Aytu Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | -4.09 | -0.24 |
| Piotroski F-Score | 3 | 4 |
| Beneish M-Score | -3.48 | -2.62 |
Calculated by StockData from Aytu Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.